Search results
Showing 1531 to 1545 of 8933 results
Evidence-based recommendations on rituximab (MabThera) with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in adults.
Evidence-based recommendations on aflibercept (Zaltrap) with irinotecan and fluorouracil-based therapy (FOLFIRI) for treating metastatic colorectal cancer after oxaliplatin-based chemotherapy in adults.
Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer (TA227)
Evidence-based recommendations on erlotinib (Tarceva) for the maintenance treatment of non-small-cell lung cancer in adults.
Evidence-based recommendations on isatuximab (Sarclisa) plus bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma in adults when an autologous stem cell transplant is unsuitable.
Show all sections
NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating hormone receptor-positive HER2-low metastatic breast cancer in adults after 2 or more endocrine treatments. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1112
NICE is unable to make a recommendation on nintedanib (Ofev) for treating fibrosing interstitial lung disease in people 6 to 17 years. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1111
Evidence-based recommendations on darolutamide (Nubeqa) with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer in adults.
View recommendations for TA1109Show all sections
Ustekinumab for treating moderate to severe plaque psoriasis (TA180)
Evidence-based recommendations on ustekinumab (Stelara) for treating psoriasis in adults.
Etanercept and efalizumab for treating moderate to severe plaque psoriasis (TA103)
Evidence-based recommendations on etanercept (Enbrel) for treating severe psoriasis in adults.
Infliximab for treating moderate to severe plaque psoriasis (TA134)
Evidence-based recommendations on infliximab for treating moderate to severe psoriasis in adults.
Apremilast for treating moderate to severe plaque psoriasis (TA419)
Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults.
Secukinumab for treating moderate to severe plaque psoriasis (TA350)
Evidence-based recommendations on secukinumab (Cosentyx) for treating plaque psoriasis in adults.
Ixekizumab for treating moderate to severe plaque psoriasis (TA442)
Evidence-based recommendations on ixekizumab (Taltz) for moderate to severe plaque psoriasis in adults.
Brodalumab for treating moderate to severe plaque psoriasis (TA511)
Evidence-based recommendations on brodalumab (Kyntheum) for treating moderate to severe plaque psoriasis in adults.
Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475)
Evidence-based recommendations on dimethyl fumarate (Skilarence) for treating moderate to severe plaque psoriasis in adults.